||||||||||Actoplus Met XR (pioglitazone/metformin XR) / Takeda Trial completion date, Trial primary completion date, IO biomarker: ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (clinicaltrials.gov) - May 7, 2019 P2b, N=39, Recruiting, Sponsor: National Cancer Institute (NCI) Recruiting --> Active, not recruiting Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019
||||||||||Actoplus Met XR (pioglitazone/metformin XR) / Takeda Enrollment open, Trial initiation date, PD(L)-1 Biomarker, IO biomarker: ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (clinicaltrials.gov) - Aug 23, 2017 P2b, N=39, Recruiting, Sponsor: National Cancer Institute (NCI) Trial completion date: Mar 2019 --> Aug 2019 | Trial primary completion date: Mar 2019 --> Aug 2019 Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Aug 2017
||||||||||Actoplus Met XR (pioglitazone/metformin XR) / Takeda Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (clinicaltrials.gov) - Apr 25, 2017 P2b, N=39, Not yet recruiting, Sponsor: National Cancer Institute (NCI) Initiation date: May 2017 --> Dec 2017 Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Nov 2018 --> Mar 2019